Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Chlorambucil
Drug ID BADD_D00429
Description A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Indications and Usage For treatment of chronic lymphatic (lymphocytic) leukemia, childhood minimal-change nephrotic syndrome, and malignant lymphomas including lymphosarcoma, giant follicular lymphoma, Hodgkin's disease, non-Hodgkin's lymphomas, and Waldenström’s Macroglobulinemia.
Marketing Status Prescription
ATC Code L01AA02
DrugBank ID DB00291
KEGG ID D00266
MeSH ID D002699
PubChem ID 2708
TTD Drug ID D0V8QT
NDC Product Code 71052-212; 76055-0025; 76388-635; 72969-010; 50683-0384; 49452-1911; 43744-066
Synonyms Chlorambucil | 4-(Bis(2-chloroethyl)amino)benzenebutanoic Acid | N,N-Di-(2-chloroethyl)-p-aminophenylbutyric Acid | Chloraminophene | Chlorbutin | NSC-3088 | NSC 3088 | NSC3088 | Leukeran | Lympholysin | Amboclorin | CB-1348 | CB 1348 | CB1348
Chemical Information
Molecular Formula C14H19Cl2NO2
CAS Registry Number 305-03-3
SMILES C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neuropathy peripheral17.09.03.003--Not Available
Neutropenia01.02.03.0040.005328%Not Available
Oesophagitis07.08.05.0010.000533%
Oliguria20.01.03.0040.000533%Not Available
Optic atrophy06.09.02.001--Not Available
Overdose12.08.01.003--Not Available
Oxygen saturation decreased13.02.01.0040.000533%Not Available
Pain08.01.08.004--
Pancytopenia01.03.03.0030.001865%Not Available
Paralysis17.01.04.004--Not Available
Paraparesis17.01.04.006--Not Available
Paresis17.01.04.008--Not Available
Peripheral motor neuropathy17.09.03.004--
Platelet count decreased13.01.04.0010.002931%
Pleural effusion22.05.02.0020.000533%
Pneumonia22.07.01.003; 11.01.09.0030.000903%Not Available
Progressive multifocal leukoencephalopathy17.16.02.002; 11.05.05.0010.000486%Not Available
Pruritus23.03.12.0010.001066%
Puberty26.03.01.003--Not Available
Pulmonary embolism24.01.06.001; 22.06.02.0010.000139%Not Available
Pulmonary fibrosis22.01.02.006--
Pyrexia08.05.02.0030.003996%
Rash23.03.13.001--Not Available
Renal failure20.01.03.0050.001332%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.000347%
Second primary malignancy16.16.01.014--
Seizure17.12.03.001--
Sepsis11.01.11.0030.000347%
Septic shock11.01.11.004; 24.06.02.0110.000208%Not Available
Squamous cell carcinoma16.16.01.0020.000533%Not Available
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages